NEW YORK, NY / ACCESS Newswire / February 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...
Vertex Pharmaceuticals (VRTX) reported fourth-quarter revenue and offered an outlook for 2025 that topped analysts’ ...
Evercore ISI has upgraded CRISPR (CRSP) to outperform from in line, citing upcoming data catalysts. Read more here.
EST Vertex Pharmaceuticals (VRTX) files automatic mixed securities shelfMaximize Your Portfolio with Data Driven Insights:Leverage the ...
Feb 10 (Reuters) - Vertex Pharmaceuticals (VRTX.O), opens new tab forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its cystic fibrosis drugs and ...
Vertex reports mixed fourth-quarter 2024 results as earnings miss estimates while revenues beat the same. Trikafta/Kaftrio ...
Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a ...